Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713019 | 0.91 | MAPT (0.62) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL6713011 | 0.85 | MCHR1 (0.54) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL14523935 | 0.83 | MAPT (0.53) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL6712765 | 0.82 | ALDH1A1 (0.52) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL4968403 | 0.81 | MAPT (0.56) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL4968406 | 0.81 | MAPT (0.56) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL6714546 | 0.78 | MCHR1 (0.48) | MAPTLMNAKMT2AMEN1RAB9A | |
| SCHEMBL6715082 | 0.74 | LMNA (0.67) | MAPTLMNAKMT2AMEN1RAB9A | |
| SCHEMBL14116634 | 0.74 | MAPT (0.43) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL3999165 | 0.72 | LMNA (0.53) | MAPTLMNAKMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885LMNA 1397/4885KMT2A 674/4885 |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885LMNA 1397/4885KMT2A 674/4885 |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885LMNA 1397/4885KMT2A 674/4885 |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885LMNA 1397/4885KMT2A 674/4885 |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885LMNA 1397/4885KMT2A 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.